...Table of Content Introduction/Overview……...………………………………………………….........2-3 Strengths...………………………………………………………………………......3-4 Weaknesses...……………………………………………………………..…………...4 Opportunities…………………………………………………………………….......4-5 Threats…….……………………………………………………………..………….....5 External Factors Impacting Decisions………………………………………………5-7 Possible Future Scenarios…………………………………………………………...7-8 Recommendations for Changes in Culture, Leadership, and/or Structure…………..8-9 Summary/Conclusions………………………………………………………………...9 Reference…………………………………………………………………………10-11 Introduction/Overview To start a company, a person or group of people must realize that it is a bumpy ride from the beginning, and that only those who are prepare enough will succeed. They have to follow multiple rigorous steps and come up with innovative strategies to prove that they have what it takes to be successful in the business. Pfizer Inc. is a company that has proven itself throughout time. They are the world’s largest research based pharmaceutical company and were also recognized by Fortune magazine as the world’s largest pharmaceutical company by profit and second largest by revenue, only next to Johnson and Johnson (Fortune, 2013). Pfizer Inc. have evolve throughout the years along with science and have been responsible for the discovery and marketing of some of the world’s most innovative drugs like, Lipitor (use to decrease cholesterol), Lyrica (use for treatment of fibromyalgia), Zithromax (a renown antibiotic)...
Words: 2350 - Pages: 10
...Organizational Systems & Corporate Responsibility – Pfizer Assignment 1 – Group MIMTG09 Does the company operate in business/industries that are by their nature socially or environmentally sensitive? Does the business as a whole face pressure from certain stakeholder groups? Pfizer is a research-based, global biopharmaceutical company. It claims to have two segments: biopharmaceutical and diversified. The latter involves animal health products, healthcare products and other personal care items (Pfizer.com/about). In the past decade Pfizer has received a lot of pressure from governments, medicine & food authorities and customer groups on mostly socially sensitive issues. It seems that the industry is characterized by corporate social responsibility issues and Pfizer seems to have contributed significantly to this image in the past (justmeans.com). Multiple tragedies in the pharmaceutical industry in the 50’s and 60’s resulted in various regulations, guidelines, and laws on the introduction of new medical products. Globalization caused a rapid increase of multinationals in the industry, but sadly coercive pressures remained national. It was in 1990 that the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) was created (Castner et al., 2007). This group is composed of more than six parties that represent various regulatory bodies in the United States, Japan, and Europe. Multinational enterprises...
Words: 1607 - Pages: 7
...Pharmaceutical Industry. Pfizer Merck & Co Bristol-Myers Squibb Vertex 2012 Revenue $59B $47B $21B $1.5B 2011 Revenue $65B $48B $19B $1.0B CEO Read Frazier Andreotti Leiden Base $1.75M $1.5M $1.6M $1.0M Annual Incentive $3.4M $2.5M $3.8M $2.1M Annual LT Incentive (Stock and Stock Options) $12.9M $7.1M $10.9M $2.5M Perks/Other $175k $0.06M $808k $0.01M Vested/Exercised Shares $5.6M Approx. Total $25M $11.1M $17.2M $5.7M According to the Proxy statements, both Pfizer and Mereck have approximately 90% of their compensation as variable, based on company performance. The large discontinuity between the two companies is mostly due to the vested or exercised shares of Pfizer’s Ian Read. Excluding this amount, the companies’ compensation plans are generally aligned with their comparable sizes and company performance. Pfizer offered the largest incentive-based payout to it’s CEO in 2012, justified by the company exceeding two of three performance metrics despite key patent losses and the leadership Read showed throughout the year. Merck ranked their CEO performance as high in a tough environment, but due to a low internal scorecard results and shareholder return rankings Frazier was awarded a lower amount of variable compensation than in 2011. Overall, both of these industry leaders seem to have incentive programs aligned with company and shareholder performance. Bristol-Meyers Squibb (BMS) stands as the odd-company-out in our analysis. Andreotti’s 2012 base pay was at the...
Words: 1322 - Pages: 6
...Key Performance Indicators for Pfizer and Merck Overview In recent years, auditors have increased the amount of attention they give to nonfinancial measures because these measures can be very helpful in assessing the risk of revenue frauds. Most frauds of this nature involve accounting personnel falsifying financial information with the intent of materially misstating the financial statements. Nonfinancial measures are much more difficult for accounting personnel to manipulate, especially those produced independently; therefore, auditors have increasingly used these nonfinancial measures to help them detect fraud. In order to utilize the nonfinancial information of a company for auditing purposes, auditors must select Key Performance Indicators (KPIs) for the company or industry. By compiling KPIs for a company and its competitor(s), the audit team can compare the nonfinancial measures and the effects they might have on the financial statements. The purpose of this paper is to identify three KPIs for Pfizer, Inc. and compare these measures with those of Merck & Company, Inc. Both of these companies focus mainly on the development and sale of pharmaceutical drugs. The success of companies in this industry relies greatly on research and development of new drugs. New drugs stay in the research and development phase until they are granted FDA approval. For this reason, we have selected number of FDA approvals as a KPI for Pfizer and Merck. The pharmaceutical...
Words: 1624 - Pages: 7
...MS Executive Summary University of Memphis, Steward A Perry, MS Equity Research Report Company: Pfizer, Inc. Ticker: PFE Price:$29.00 on 10/04/13 Recommendations: Price Target One Year: Trailing P/E Ratios = | Forward P/E Ratio = | PEG Ratio = .046 | Expected return for a Security = | Expected Risk for a security = | Beta β = | Sharpe Ratio = | Treynor’s Reward to Volatility Ratio = | Financial Summary * Expected Returns * Trailing P/E Ration * Forwarding P/E Ratio * Dividends Per Share * PEG Ratio * Market Capitalization * Growth in Revenues for the Last 12 Months Risk Measurements * Beta β * Standard Deviation * Sharpe Ratio * Treynor’s Reward to Volatility Ratio Highlights Qualitative Analysis Company Profile Industry Overview SWOT Analysis * Strengths * Weaknesses * Opportunities * Threats Porter’s 5 Competitive Forces I. The threat of substitute products II. The threat of new competitors III. The intensity of competitive rivalry IV. The bargaining power of customers V. The bargaining power of suppliers Management Financial Statement Analysis Financial Ratio Analysis The financial ratios in this report has been computed by using the income statements of Pfizer (PFE) during the fiscal year 2012. The income statements were obtained from the annual report submitted to the Security and Exchange Commission...
Words: 726 - Pages: 3
...Company Overview Company Overview Bristol Myers Squibb (BMS) is a world-wide Bio-Pharmaceutical company which focuses on “discovering, developing, and delivering innovative medicines that helps patients prevail over serious diseases” (BMS 1). In 1887, John Ripley Myers and William McLaren Bristol bought a near-bankrupt pharmaceuticals company centered in Clinton, New Jersey. Today, the company as a whole focuses primarily on developing medicines to fight cancer, hepatitis, HIV/AIDS, and diabetes, but the beginnings years of the company had an extremely different outlook. It took nearly fifteen years before the company started turning a profit, but ever since the turn of the century in 1900, BMS has been able to stay in the black. The company’s first two successful products was the first toothpaste to include a disinfectant called Ipana, and a laxative mineral salt called Sal Hepatica. By 1924, the company had gone international and profited a million dollars for the first time. Bristol Myers Squibb was also able to issue stock for the first time in 1929, as it was traded on the New York Stock Exchange. Throughout the 1960’s and 1970’s, the company was able to expand into the baby formula and antibiotics market, as well as creating the first electronic toothbrush. In 2001, the company was voted the “Most Admired Pharmaceutical Company” by Fortune Magazine, and today the company has continued its progression into the fields of oncology and antibiotics. Bristol Myers Squibb...
Words: 2280 - Pages: 10
...ETHICAL CULTURAL ANALYSIS: Pfizer Incorporated Prepared by Benjamin Smith Submitted in partial fulfillment of Thomas Edison State College course: 2014AUG PHI-384-GS004: Ethics and the Business Professional. October 23, 2014 [pic] Introduction Pfizer is the second-largest biopharmaceutical company in the world, and largest research-based company in the world (Herper 2014). They are the producers of some of the most popular names in prescription drugs, including Lipitor®, Viagra®, Xanax®, and Zoloft®. They are also one of the leading names of over the counter drugs and supplements such as Advil®, Centrum®, and Robitussin®. Pfizer employs over 78,000 personnel all over the world in most every continent. Its operations encompass researching and development of new medications, vaccines, and therapies; government regulatory compliance; and providing care and support for global healthcare programs. My interest in Pfizer is that I plan on changing careers into the medical field as a physician or research scientist. As the leading research-based pharmaceutical company, I would aspire to work with neuroscientist Dr. Michael Ehlers and his team. This analysis will review Pfizer Incorporated as a responsible, ethical company by analyzing its mission statements, core values, published principles, and code of ethics, how these are reflected in their actions and which ethical concepts are displayed in these actions; how Pfizer prevents and responds to problematic...
Words: 4047 - Pages: 17
...| Pfizer Stock Report | | Fall 2013 Research Project | | Pfizer Stock Report | | Fall 2013 Research Project | Saint Joseph’s University Contents II. Introduction 2 III. Macroeconomic Review 3 IV. Stock Market Analysis 6 V. Industry Analysis 8 VI. Company Strategic Analysis 10 VII. Company Financial Analysis 12 VIII. Application of Valuation Methodologies 13 IX. Conclusion and Recommendations 15 X. Exhibits 16 A. Exhibit A 17 B. Exhibit A 17 XI. References 18 Introduction Pfizer, headquartered in New York, NY, is committed to applying science and global resources to improve the health and well-being of individuals of all stages of life. Ian Read, CEO, leads the company through innovation and solid long term performances on the NYSE. Pfizer is also on the London, Euronext and Swiss exchanges. They make every effort to provide everybody with access to affordable, top of the line, safe remedies and health related services to those in need. Some of Pfizer’s most famous products include, Lipitor, Lyrica, Diflucan, Zithromax, Viagra, and Celebrex. Pfizer is committed to providing sustainable solutions to the biggest health issues in the world by continuously reviewing and updating their products and services to reduce their environmental footprints. The company maintains the highest ethical standards in all that they do such as sales and marketing to research and development. Pfizer, along with all industry...
Words: 4411 - Pages: 18
...Executive Summary: Pfizer-Wyeth Merger Deal Overview: On January 25, 2009, Pfizer and Wyeth entered into the merger agreement, pursuant to which, subject to the terms and conditions set forth in the merger agreement, Wyeth will become a wholly-owned subsidiary of Pfizer. Upon completion of the merger, each share of Wyeth common stock issued and outstanding will be converted into the right to receive, subject to adjustment under limited circumstances, a combination of $33.00 in cash, without interest, and 0.985 of a share of Pfizer common stock in a taxable transaction. Pfizer will not issue more than 19.9% of its outstanding common stock at the acquisition date in connection with the merger. The exchange ratio of 0.985 of a share of Pfizer common stock will be adjusted if the exchange ratio would result in Pfizer issuing in excess of 19.9% of its outstanding common stock as a result of the merger Deal Terms Breakdown: Transaction Value Transaction Consideration Purchase price per WYE share $50.19 Existing Cash Used $22,213 32.7% Cash per WYE share $33.00 New Debt $22,500 33.1% PFE stock value per WYE share $17.19 Total Cash $44,713 65.8% PFE shares per WYE share 0.985 Stock Consideration $23,289 34.2% Premium to 1/23/09 WYE price 29.3% Total Consideration $67,303 100.0% Total WYE shares (MM,diluted) 1,341 Total Equity...
Words: 8308 - Pages: 34
...High-Technology Acquisitions Final Project -Acquisition Proposal: To Acquire: May 2012 Table of Content Executive Summary I A. Purpose I B. Background I C. The Rational for the Acquisition I D. Standalone, Synergy and Premium Valuations II E. Integration Plan II Part 1 - The Rational of the Acquisition 1 1. Pfizer's Strategy 1 1.1. Pfizer Growth Strategy 2 2. Pfizer's Road Map 4 2.1. Pfizer's Acquisitions Rational 4 3. The strategy behind the acquisition 5 3.1. Acquisition Motives 5 3.2. M&A vs. Alliance 5 4. Target Identification 7 4.1. Protalix - an R&D Acquisition 9 5. Synergy Analysis 10 6. Standalone, Synergy and Premium Valuations 12 6.1. Market Value 12 6.2. Trading and Transaction Multiples Valuations 12 6.3. Discounted Cash Flow (DCF) Valuation 14 6.3.1. DCF Methodology and Assumptions 14 6.3.2. Summary of the Standalone and the Synergy DCF Valuation 15 6.4. Premium 16 6.5. Walk-away Price, Net Value Creation and Financial Feasibility 17 Part 2 - The Integration Plan 18 Bibliography 21 APPENDIXES 22 Appendix 1 - Pfizer's Executive Leadership Team 23 Appendix 2 - Pfizer's Organizational Structure Scheme 24 Appendix 3 - Five Forces Analysis for the Pharmaceutical Industry 25 Appendix 4 - Pfizer's PEST Analysis 27 Appendix 5 - Level of Competition Between the Acquirers & the Uniqueness of the Acquired Company 31 Appendix 6 - Acquisition Motives 33 Appendix 7 - Protalix...
Words: 10031 - Pages: 41
...continue to be profitable despite competition from generic pharmaceuticals, barriers to innovation, and safety regulation. An industry overview Brand Name Pharmaceutical Manufacturing in the United States is one of the largest industries in the world today. This industry produces prescription and over-the-counter drugs as well as biologic products that are primarily intended for the treatment of human illnesses (Zhong). Its major products and services include other pharmaceutical preparations, biological products, oncological products, medicinal and botanical products, respiratory agents, lipid regulators, anti-diabetics, and in-vitro diagnostic substances (Turk). Similar industries include generic pharmaceutical, cosmetic and beauty products, scientific research and development, and biotechnology manufacturing in the United States (Zhong). The Center of Drug Evaluation and Research (CDER) of the Food and Drug Administration (FDA) (Zhong) is the government agency in charge of regulation and oversight of this industry. It consists of 1,575 businesses. Major players and their market shares consist of Pfizer Inc. (10.9%), Merck and Co. Inc. (10.4%), Johnson & Johnson (8.0%), Amegen (7.4%), Eli Lilly & Company (7.2%), and Abbvie Inc (6.4%) (Turk). In 2013 it brought in $165.0 billion dollars in revenue and $35.6 billion in profits. Between the years of 2012 and 2017, the brand name pharmaceutical industry will have an annual growth of 0.4% (Zhong). Increased globalization and healthcare...
Words: 1160 - Pages: 5
...Elwood Leftridge Professor Joanne Land Kazlauskas GPS-4278W 05-01-2013 Putting It All Together a Look at Pfizer Pharmaceutical Company Pfizer Pharmaceutical Company is not only the world’s largest research pharmaceutical company in the world, but also the leader of technological advances. This organization has been in operation for over 160 successful years, and has over 117,000 diverse workers employed worldwide from all facets of life. It is important to employ a solid employee workforce within an organization, this can either make or break an organization. “In 2012 Pfizer was ranked #40 among Fortune 500 with 2011 revenue totaling almost 68 million dollars, and a profit margin of over 10 million dollars”(CNN Money, 2013). The purpose of this paper is to break apart Pfizer into four different organizational perspectives, analyze them, and then put them back together again. Or as with the title of the textbook (Reframing Organizations: Artistry, Choice, and Leadership. Vol. 4) suggests to reframe organizations to a particular frame or frames. The frames that I will be using to analyze Pfizer Pharmaceuticals will be the Structural Frame, the Symbolic Frame, the Human Resources Frame, as well the Political Frame. To begin, I will describe the Pfizer organization using Bolman & Deal’s Structural Frame perspective. The structural components that I will discuss will be the Division of Labor, the Leadership Structure, and Roles and Responsibilities of the organization...
Words: 5349 - Pages: 22
...New Product Launch Plan in the market By Pfizer Pharmaceutical Ltd Company In the year of 2014 in the United States of America. Overview: As the CEO of the Pfizer Pharmaceuticals Ltd, I would like to represent our new product launch plan that includes our company background, new drug information, new product launch plan, estimated costs of the projected plan, market analysis, contractual issues, evaluation, risk management staff and the general approaches etc. I would like to say our new product called as a DuaveeTM which was made by the Wyeth Pharmaceuticals which is wholly-owned subsidiary of our company Pfizer pharmaceutical Ltd and it is also a part of broader research collaboration with Ligand Pharmaceutical incorporated. We are going to plan this product in the market next year 2014. All the information related to launch schedules and estimated costs also included in the project. Our company project includes mainly six elements and we will focus mainly on these six types of elements such as: Project Definition: Objectives: According to me, it is the best success of the company for achievement in the fields of the Women’s medicines. Main objectives of the company are that our company will get more profit by launching the new product and we also will get new reputation in the market. Before launching this product we must have to understand what is the product contains? And how it will help? So here I want to describe something about the product that is need to...
Words: 1826 - Pages: 8
...Pfizer Executive Summary Company Overview World’s largest global research-based biomedical and pharmaceutical company that discovers, develops, manufactures and markets safe and effective medicines. Mission To be the world’s most valued company to patients, customers, colleagues, investors, business partners and the communities where we work and live. Pharmaceutical Products Aricept Genotropin Spiriva Aromasin Geodon/Zeldox Sutent Caduet Lipitor Vfend Camptosar Lyrica Viagra Celebrex Norvasc Xalatan/Xalacom Chantix Rebif Zmax Detrol/Detrol LA Relpax Zoloft Eraxis Revatio Zyvox Animal Health Products BoviShield Draxxin RespiSure/Stellamune Cerenia Excede Revolution/Stronghold Clavamox/Synulox Improvac Rimadyl Convenia Lutalyse Silentrol Dectomax Naxcel/Excenel Financials Stock Symbol: PFE Price Range: $11-$18 Sales (2008): $48,296,000,000 Net Income: $8,104,000,000 Net Assets: $109,892,000,000 Key Executives CEO: Jeff Kindler CFO: Frank D'Amelio CMO (Chief Medical Officer): Freda C. Lewis-Hall Key Competitors GlaxoSmithKline Johnson & Johnson Novartis AG Roche Holding-AG Sanofi-Aventis Mergers and Acquisitions (2008-2009) Wyeth: announcement of merger 1/26/09, biopharmaceutical Auxilium Pharmaceuticals: 12/08, develops Xiaflex-first in class biologic for treatment of Dupuytren’s contracture and Peyronie’s Disease Schering-Plough...
Words: 7035 - Pages: 29
...Pharmaceutical Supply Chain Abstract • The global pharmaceutical supply chain is very complex and critical to a $650 billion dollar value industry which ensures the world population has necessary medicines. • Manufacturers have the responsibility to produce sufficient quantities of drugs to meet a growing global demand while maintaining quality to ensure safety. • Global and local regulatory agencies around the world have a daunting task to monitor manufacturers, raw material suppliers, and stem counterfeit pharmaceutical production. • Wholesale distributors, importers, and retail pharmacies have a large amount of power in the supply chain as they pull the demand from the manufacturers and provide the medicines to end-consumers. • In a changing industry where there are fewer blockbuster drugs and increasing use of generic offerings, manufacturers as well as participants at all levels of the supply chain must look for areas to improve efficiencies to be profitable in the long-run. Pharmaceutical Supply Chain Analysis 2 Introduction A transparent and efficient pharmaceutical supply chain contributes significantly towards improving the availability of essential medications. The reality across the world is that pharmaceutical supply and distribution consists of different stakeholders from both the public and private sectors to create complex systems. In a heavily regulated field, globalization has placed increasing demands on regulatory agencies to ensure the safety and...
Words: 6177 - Pages: 25
